Prof. Krejcis team is researching FGF signaling mechanisms, in particular, pathological FGFRs, such as FGFR3, which causes achondroplasia. His team also manages ReACH, standing for Registry of Achondroplasia, which means to serve as a tool for clinicians and healthcare providers to conduct research.

This news article, written by 4-traders and the pharma letters, describes the path that led to the agreement between Chugai, who discovered CNP, and BioMarin.

Researchers are failing to submit their clinical trials' results in clinicaltrials.gov.

This study not only means to understand the natural history of achondroplasia (what complications occur, how often, average life span, etc.), but also aims to build a global patient registry. What is the purpose of a patient registry? Know more about it here.

What are the next steps for BMN-111? Here you can find a timetable for what is planned for this rdug in development.

New treatments using the CRISPR/Cas9 gene editing tool are being developed. In order to understand how these would work here is a short vídeo and article about this possible excision of the mutation and substitution with the non-mutated gene.